| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Former 10% Owner | Director, 10% Owner
5 companies
Gadicke Ansbert is a Director, 10% Owner at KLRS, with reported holdings spanning 5 companies. Recent filings cover 4 purchases and 117 sales. Those positions are worth an estimated $620.8M at current prices.
Our model assigns Gadicke Ansbert a strong insider score of 85/100, based on 79 past trades. Over a 12-month horizon, 98.0% of those trades were profitable, with an average 12-month return of +56.6%.
Gadicke Ansbert's largest disclosed position is in CGEM as Director, 10% Owner, worth about $222.3M. The recent filings there lean toward selling, a net 2,396 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | HOWL Werewolf Therapeutics, Inc. | 10% Owner | Sell | 4,386 | $1.05 | $4,605.30 | - | +11.7% | -27.0% | |
| Sep 16, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 3,556 | $29.06 | $103,337.36 | - | -44.7% | -56.6% | |
| Sep 15, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 15,401 | $29.17 | $449,174.04 | -0.2% | -46.2% | -55.0% | |
| Sep 13, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 26,468 | $29.23 | $773,719.99 | -0.3% | -44.2% | -54.8% | |
| Sep 8, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 55,364 | $29.20 | $1,616,749.39 | -0.7% | -39.6% | -52.5% | |
| Sep 2, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 27,669 | $29.50 | $816,352.16 | -0.4% | -44.2% | -55.5% | |
| Aug 30, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 50,489 | $29.24 | $1,476,135.07 | -0.6% | -40.5% | -57.2% | |
| Aug 25, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 120,592 | $29.29 | $3,531,819.71 | -1.5% | -28.9% | -49.8% | |
| Aug 11, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Sell | 2,857 | $29.05 | $82,995.85 | - | -21.8% | -53.9% | |
| Jul 12, 2021 | RPTX Repare Therapeutics Inc. | 10% Owner | Sell | 62,079 | $33.55 | $2,082,867.70 | -1.6% | -42.1% | -55.5% |